Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Pluristem Therapeutics Inc (NASDAQ:PSTI)

2.35
Delayed Data
As of 12:42pm ET
 -0.0599 / -2.49%
Today’s Change
2.27
Today|||52-Week Range
3.78
-6.00%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$189.2M

Company Description

Pluristem Therapeutics, Inc. is a bio-therapeutic company, which develops standardized cell therapy products for the treatment of life threatening diseases. The company's patented PLX (PLacental eXpanded) cells drug delivery platform releases a cocktail of therapeutic proteins in response to a variety of local and systemic inflammatory diseases. It offers to the commercialization of unrelated donor-patient (allogeneic) cell therapy products for the treatment of several severe degenerative, ischemic and autoimmune disorders. Pluristem Therapeutics develops pipeline of products derived from human placenta, a non-controversial, non-embryonic, adult stem cell source. It intends to commercialize cell therapy production technologies and products. The company operates in Israel and United States of America. Pluristem Therapeutics was founded on May 11, 2001 and is headquartered in Haifa, Israel.

Contact Information

Pluristem Therapeutics, Inc.
MATAM Advanced Technology Park
Haifa Haifa 31905
P:972747107171
Investor Relations:
972747108631

Employees

Shareholders

Individual stakeholders7.49%
Other institutional6.64%
Mutual fund holders1.91%

Top Executives

Zami AbermanChairman & Chief Executive Officer
Yaky YanayPresident & Chief Operating Officer
Boaz Gur-LavieChief Financial Officer & Secretary
Racheli OfirVice President-Research & Intellectual Property
Esther Lukasiewicz-HagaiVice President-Clinical & Medical Affairs